Cadila Steps Into Cardiac Care with New Beta-Blocker Therapy

• Cadila launches Biscado, marking entry into beta-blocker therapy

• Biscado addresses India-specific cardiac risks, like a high resting heart rate

• Bisoprolol outperforms Metoprolol and Carvedilol in survival outcomes

Ahmedabad-based company, Cadila Pharmaceuticals, has entered the space of beta-blocker therapy by introducing Biscado (Bisoprolol), a notable milestone in the improvement of its portfolio in cardiac care.

Bisoprolol is one of the cardioselective beta-1 adrenergic blockers. It is used to treat high blood pressure, chronic heart failure, and angina. Efficient lowering of heart rate and blood pressure reduces cardiac workload, decreases the risk of hospitalisation in patients with heart failure, and thus enhances outcomes.

The launch of Biscado is particularly relevant in the Indian context, where patients often exhibit higher empathetic activity and elevated resting heart rates, the factors strongly associated with poorer cardiovascular outcomes. Research indicates that every 10 bpm increase in resting heart rate is linked to a 20 percent rise in cardiovascular mortality, underscoring the need for targeted interventions like Bisoprolol.

Biscado has a strong foundation of international studies to establish its clinical value. The groundbreaking CIBIS-II trial proved Bisoprolol efficacy with a 34 percent decrease in overall mortality, a 44 percent reduction in sudden cardiac death, and a 36 percent reduction in hospitalization due to congestive heart failure when compared to the control group. Comparative studies add to this evidence to provide insight into Bisoprolol's superiority in efficacy, reducing mortality by 20 percent more than Metoprolol Succinate and possessing better survival statistics compared to Carvedilol in the treatment of heart failure.

Also Read: New Treatment Aumolertinib Approved for EGFR-Positive NSCLC

Additional confirmation is provided by the TIBBS study, which noted lower rates of death, heart attack, and hospitalization among patients with angina treated with Bisoprolol compared with calcium channel blockers.

Recognizing the need for comprehensive cardiovascular management, Cadila plans to roll out Biscado not only as monotherapy but also in Fixed-Dose Combinations (FDCs) with other antihypertensive agents. This approach strives to offer integrated treatment solutions across the full range of cardiac care.

With the introduction of Biscado, Cadila Pharmaceuticals strengthens its commitment to providing advanced, evidence-based therapies in cardiovascular healthcare and addressing the growing hindrance of heart disease in India.